BG Medicine

BG Medicine (NASDAQ: BGMD) is a publicly traded developer of the BGM Galectin-3® Test. The company is focused on the development and delivery of diagnostic solutions to aid in the clinical management of heart failure and related disorders. BG Medicine launched an IPO in 2011 at a total of $80M.


Company Profile

BG Medicine Logo